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ABSTRACT: The design of pharmaceutical cocrystals has
initiated widespread debate on the classiﬁcation of cocrystals.
Current attempts to classify multicomponent crystals suﬀer
from ambiguity, which has led to inconsistent deﬁnitions for
cocrystals and for multicomponent crystals in general. Inspired
by the work of Aitipamula et al. (Cryst. Growth Des. 2012, 12,
2147−2152), we present a feasible classiﬁcation system for all
multicomponent crystals. The present classiﬁcation enables us
to analyze and classify multicomponent crystal structures
present in the Cambridge Structural Database (CSD). This
reveals that all seven classes proposed are relevant in terms of frequency of occurrence. Lists of CSD refcodes for all classes are
provided. We identiﬁed over 5000 cocrystals in the CSD, as well as over 12 000 crystals with more than two components. This
illustrates that the possibilities for alternative drug formulations can be increased signiﬁcantly by considering more than two
components in drug design.
■ INTRODUCTION
The design of multicomponent crystals, such as solvates or
salts, provides a means to alter the physicochemical properties
of crystals without changing the chemical properties of the
molecule of interest. This is particularly useful in the case of
active pharmaceutical ingredients (APIs). For example,
sulindac, a non-steroid anti-inﬂammatory drug, can be crystal-
lized with diﬀerent solvents to alter its dissolution rate.1 Other
APIs may exhibit increased water solubility as a salt, such as the
sodium salt of naproxen.2 Although solvates and salts are
commonly used in this context, the formation of cocrystals has
only recently been considered for APIs, which has signiﬁcantly
increased the solid forms available for formulation.3 The
number of solvents and counterions that can safely be included
in pharmaceuticals is limited; safe coformers, on the other hand,
are plentiful:4 many are mentioned in the generally recognized
as safe list (GRAS),5 which lists hundreds of compounds, and
even more are found in the everything added to food in the
U.S. list (EAFUS),6 which lists thousands of compounds
suitable as food additives. Both of these lists are managed by
the U.S. Food and Drug Administration (FDA).
In December 2011, the FDA announced a draft guidance on
classiﬁcation of cocrystals as “dissociable API-excipient
molecular complexes”.7 This draft guidance provoked a
response from the academic world in a paper urging for an
alternative regulatory classiﬁcation.8 In the response, titled
Polymorphs, salts and cocrystals: what’s in a name?, Aitipamula et
al. challenged the regulatory classiﬁcation by proposing the
merging of cocrystals with salts. They argue that the two should
not be subject to separate sets of rules and regulations because
cocrystals and salts are sometimes diﬃcult to distinguish and
because coformers, similar to ions, often act more like active
ingredients than like excipients.
Apart from the many opinions and pharmaceutical issues that
are addressed by the FDA, the industry, and academia, a
practical question is how relevant the various classes are in
terms of the number of crystal structures and how to use
crystallographic databases in order to classify entries on the
basis of concrete rules. This is the main goal and challenge of
the present article.
■ PREVIOUS CLASSIFICATION
The scientif ic classiﬁcation of multicomponent crystals into
solvates, salts, and cocrystals is presented in Figure 1a. The
aggregation states mentioned below refer to the pure un-
ionized residues at room temperature. According to this
classiﬁcation, solvate crystals contain a solid residue and a
liquid residue; salts contain two ions, one of which is a solid;
and cocrystals contain two solid residues. These classes are not
mutually exclusive and yield seven subclasses: the true solvate
(yellow), salt (red), and cocrystal (blue) and the classes at the
intersections of these circles (e.g., solvated cocrystal, green).
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Aitipamula et al. suggest three alternative regulatory classi-
ﬁcations in which cocrystals and salts belong to the same
regulatory class. These three alternative regulatory classifcations
are described as follows in the original paper:
(1) One class where all solid forms of APIs are classiﬁed
together.
(2) Two classes: (1) single-component APIs, their poly-
morphs, and solvates and (2) salts, cocrystals, and their
polymorphs or solvates.
(3) Three classes: (1) single-component APIs and their
polymorphs; (2) salts, cocrystals, cocrystals of salts,
binary salts, and their polymorphs; and (3) solvates and
hydrates of single-component or multicomponent APIs
and their polymorphs.
These classiﬁcations are presented in Figure 1b−d,
respectively, where the diﬀerent subclasses, represented by
colored shapes, are combined in diﬀerent regulatory classes,
indicated by the black dotted lines. In spite of the
recommendations by Aitipamula et al, the FDA chose not to
alter the existing regulatory classiﬁcation of solvates and salts9
but to create a third class, “cocrystals”; this arrangement is
depicted in Figure 1e. The three FDA regulatory classes apply
to (1) single-component crystals and their (pseudo)-
polymorphs, (2) salts and their (pseudo)polymorphs, and (3)
cocrystals and their (pseudo)polymorphs. (The FDA uses the
term polymorph for pseudopolymorphs, so solvates are
considered polymorphs in their guidances.) The FDA
classiﬁcation does not specify the overlap region of cocrystals
and salts.
A comprehensive classiﬁcation should be unambiguous,
complete, and describe several mutually exclusive classes. The
approach of Aitipamula et al. is consistent with current scientiﬁc
thought and also a good starting point for that. In Figure 1a,
however, the classes are not unambiguously deﬁned and rules
for classiﬁcation are not proposed. For example, is it not clear
how a crystal consisting of A+ (solid), B− (solid or liquid), and
C (liquid) should be classiﬁed. If we want a clear and complete
classiﬁcation and accompanying nomenclature, then we have to
expand the deﬁnitions of the three circles and deﬁne each of the
seven subclasses created by the overlap of three circles
according to the principles of set theory. Since the interest in
multicomponent crystallization has shifted from fundamental
research to a widely studied ﬁeld in academia and industry, a
proper classiﬁcation of the diﬀerent crystals of interest is
important. It allows for proper regulatory classiﬁcation and
enables targeted exploration of classes that are promising for
the optimization of APIs. Therefore, we propose concrete rules
for the classiﬁcation of multicomponent crystals and have
applied this classiﬁcation to the Cambridge Structural Database
(CSD). Pharmaceutical salts and solvates represent two well-
studied classes, in contrast to other multicomponent classes.
The application to the CSD allows us to estimate the potential
impact of these other multicomponent classes not only for
cocrystals but also for crystals with more than two residues: If
the number of components in a crystal is not restricted to one
or two, then this will further increase the posibilities for
alternative solids of APIs. In the next section of this article, we
propose strict deﬁnitions for the seven subclasses found in
Figure 1 and highlight issues that inevitably emerge. We then
describe our approach to apply this classiﬁcation to the CSD,
followed in the Results and Discussion section by an example
from the CSD for each subclass, up to a crystal classiﬁed as a
cocrystal salt solvate. We also present the distribution of CSD
crystals over the seven subclasses and provide lists of CSD
refcodes for all subclasses.
■ CLASSIFICATION
Before exploring the multicomponent crystals in the CSD, we
need to deﬁne all of the classes that we want to distinguish. For
the classiﬁcation to be unambiguous, all crystals must fall into
exactly one subclass.
Multicomponent crystals can be deﬁned as crystals with two
or more diﬀerent (diﬀerent 2D structure, diﬀerent elements, or
diﬀerent but not opposite chirality) residues in the crystal
lattice. (A residue is considered to be a complete set of
covalently bonded elements. In this article, covalent bonds will
be deﬁned by the connectivity records of the CSD dataﬁle
used.) We refer to the number of residues in the asymmetric
unit as ZR such that ZR > 1 for multicomponent crystals and ZR
= 1 for single-component crystals.
We distinguish residues as either an ion, a solvent, or a
coformer. These residue types are similar to the charged
residue, the neutral liquid residue, and the neutral solid residue,
respectively, that are used for classiﬁcation by Aitipamula et al.
Figure 1. (a) Three overlapping multicomponent crystal classes,
visualized as circles, adapted from Aitipamula et al.;8 (b−e) dotted
lines separate diﬀerent regulatory classes proposed by8 (b) one
regulatory class for all solids; (c) two regulatory classes: one single-
components and solvates and one remainder class; (d) three
regulatory classes: one single components, one cocrystals and salts,
and one solvates class (including cocrystal and salt solvates); and (e)
FDA regulatory classes.
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Some issues arise with the labeling of residues that we need
to consider before deﬁning our ion, coformer, and solvent
residues. One issue is that of charge transfer: when is charge
transfer considered signiﬁcant? In principle, this question can
be answered by performing an accurate charge density analysis,
e.g., on the basis of X-ray diﬀraction or density functional
calculations. In the CSD data used in this study, there is no
concept of delocalized charge; charges are associated with
speciﬁc atoms and are integral. This means that the issue of
partial charge transfer can be solved in a pragmatic way for this
study. We are aware of the fact that not all CSD entries were
carefully analyzed with respect to charge transfer. Because only
residues with a net overall charge are considered ions,
zwitterions are considered coformers. On the other hand, the
residues of ionic liquids would be considered ions, according to
the above-mentioned standards, even though they are known to
act as solvents.
Another issue is how to diﬀerentiate between solvents and
coformers based on the crystallographic data. Before we deﬁne
the two, we consider the deﬁnitions of true cocrystals found in
scientiﬁc literature. The name cocrystal is mentioned in many
diﬀerent contexts, two of which stand out:
(1) Multicomponent crystals of neutral residues, individually
solid at room temperature10
(2) Multicomponent crystals of neutral residues, not
commonly used as solvents11
As an example, take a theophylline DMSO crystal (Figure 2)
that was crystallized at a laboratory at MIT from a DMSO
solution and transported to a poorly heated classroom at the
University of Calgary. Both above-mentioned cocrystal
descriptions agree that this is a solvate since DMSO is a
commonly used solvent with a melting point of 19 °C at
atmospheric pressure and therefore a liquid in the lab. Now,
regardless of the local room temperature in the Calgary
classroom, the nature of the crystal is the same, even when pure
DMSO may be solid in the colder class room and liquid in the
lab. Hence, a strict deﬁnition is necessary to ensure that the
solvate is always classiﬁed as such. We deﬁne a solvent as any
neutral residue that is liquid under ambient conditions (T =
293.15 K, P = 105 Pa).
To summarize, our residue types are deﬁned as follows.
ion: a residue with a nonzero formal charge
solvent: a neutral residue that is liquid at ambient conditions
coformer: a neutral residue that is not a solvent
Now, we can continue by deﬁning the subclasses derived
from these residue types. Our classiﬁcation will follow the
classiﬁcation system proposed by Aitipamula et al. (Figure 1a):
three main classes, named solvate, salt, and cocrystal, that form
seven subclasses. Three of the subclasses belong to only one
main class, three belong to two main classes, and one belongs
to all three main classes. The seven subclasses will be called true
salt, true solvate, true cocrystal, salt solvate, cocrystal solvate,
cocrystal salt, and cocrystal salt solvate. First, however, we must
expand the deﬁnitions of the main classes (solvate, salt, and
cocrystal) because the classiﬁcation scheme in Figure 1a is not
complete.
This issue becomes evident when viewing the isonicotina-
mide (INA) pyromellitic acid hydrate in Figure 3: it contains an
ion pair (A+ (solid), B− (either)) and a solvent (C (liquid)). It
seems intuitive to classify this as a salt solvate; however,
according to Aitipamula et al, a solvate requires the presence of
a neutral, solid residue (see Figure 1a). In fact, with their
deﬁnitions, the combination of ions and a solvent is not
classiﬁable. The same holds for other three component crystals,
e.g., one coformer and two ions. In other words, the
classiﬁcation is not complete, and we are forced to reconsider
the deﬁnitions of the main classes (salt, solvate, cocrystal) such
that the INA crystal (Figure 3)and actually all combinations
of residuescan be classiﬁed, in line with set theory.
Therefore, we propose the following deﬁnitions of the main
classes:
salt: a crystal containing at least two ions
solvate: any crystal with a solvent molecule plus either a
coformer or at least two ions
cocrystal: a crystal with a coformer molecule plus either
another coformer or at least two ions
Table 1 shows the possible compositions of solvates, salts,
and cocrystals in main classes on the basis of residue types ion,
solvent, and coformer. The second part of the table, subclasses,
summarizes the possible compositions of the seven subclasses
that arise from the main classes. The seven subclasses are now
deﬁned as follows:
true solvate: one or more solvents and exactly one coformer,
no ions
true salt: only ions
true cocrystal: only coformers
salt solvate: one or more solvents and two or more ions, no
coformers
cocrystal solvate: one or more solvents and two or more
coformers, no ions
Figure 2. Unit cell of the theophylline DMSO solvate, from CSD
(RIGYEM); hydrogens are omitted for clarity. DMSO is a borderline
solvent, with a melting point of 19 °C.
Figure 3. Asymmetric unit of protonated INA with a pyromellitic acid
counterion and water, HEVPUU. This combination of a salt with a
solvent molecule is not classiﬁable in the scheme presented in8 Figure
1a.
Crystal Growth & Design Article
DOI: 10.1021/acs.cgd.6b00200
Cryst. Growth Des. 2016, 16, 3237−3243
3239
cocrystal salt: one or more coformers, two or more ions, no
solvents
cocrystal salt solvate: one or more solvents, two or more
ions, one or more coformers
The classiﬁcation procedure is now straightforward: the INA
crystal example holds two ions, one solvent, and no coformers,
which means that it falls into the salt main class as well as the
solvate main class and thereby classiﬁes as the salt solvate
subclass. Using the number of each residue type, one can
directly determine the subclass.
By redeﬁning the terms solvate, salt, and cocrystals, we have
solved ambiguities that were present in classiﬁcation attempts
so far. In Figure 4, the three circles that visualize the
classiﬁcation are broken down into the seven newly deﬁned
subclasses. It can be seen that the true solvate, true salt, and
true cocrystal have a minimum of two residues, whereas three
intersection classes require at least three residues, and the
cocrystal salt solvate requires at least four residues.
Finally, it is noteworthy that in this approach the minimum
requirements of a cocrystal salt, salt solvate, and cocrystal salt
solvate are less than the sum of the corresponding true solvate,
true salt, and true cocrystal requirements. We emphasize that
the subclasses are created from the overlapping deﬁnitions of
the solvate, salt, and cocrystal main classes.
■ APPLICATION TO THE CSD
Data Acquisition. ConQuest 1.17 was used to search the
CSD 5.36 + update (February 2015). All organic entries
containing 3D coordinates, no errors, and no disorder were
included in our initial analysis. The reason for not including
metal−organic crystals is that in these crystals the interaction
between the metal and a nonmetal is treated as a covalent bond
or as aromatic, pi, or delocalized. Since we speak of a residue as
a covalently bonded unit, this makes it diﬃcult to assign
elements of such entries to residues: sometimes a residue
includes the metal, sometimes it does not; therefore, only
organic entries were included. The refcode list of these entries
was exported, as well as the Protein DataBase ﬁle (pdb) and the
mol2 ﬁle (mol2).
Preprocessing. Following the presented classiﬁcation rules,
true polymorphs should be classiﬁed identically; therefore, we
aim to include only one polymorph of each crystal. To this end,
crystals with the same CSD refcode but diﬀerent sequential
number were excluded, and only the highest number was
included in the data set. This procedure also excludes all but the
newest redeterminations.
The atomic charges in the pdb ﬁle were replaced by the
charges in the mol2 ﬁle (when exporting CSD entries to pdb
using ConQuest, some information is lost and all charges are
set to 0).
Processing. All residues, i.e., covalently bonded units, in a
crystal were identiﬁed, and identical residues were deﬁned as
having identical connectivities, atom types, and atomic charges.
All residues within one entry were indexed by our in-house
software Maruchi. Maruchi distinguishes between connectivities
of residues using an extended connectivity algorithm based on
the Atomic Walk Counts.12 This index is used to determine the
number of unique (nonidentical) residues in a crystal, ZR.
Because the possible subclasses depend on ZR, the results in the
next section will be presented for ZR = 2, ZR = 3, and ZR ≥ 4
separately.
In each entry, the number of ions was determined by the
number of residues with a net charge. All neutral liquid residues
qualify as a solvent, but for practical purposes, we used a list of
80 known solvents, which are liquid under ambient conditions,
59 of which were published by Görbitz et al.13 The CSD was
searched for solvates of these 80 commonly used solvents in
their un-ionized state using ConQuest. The number of
coformers is determined by taking the total number of residues
in an entry, as determined by Maruchi, and subtracting the
number of ions and solvents (eq 1). Since the list of solvents
does not include more exotic solvents, some residues are falsely
identiﬁed as coformers.
= + +n n n ncomp cof solv ion (1)
After the number of each residue type has been determined
for each entry, the multicomponent entries are labeled true
solvate, true salt, true cocrystal, salt solvate, cocrystal solvate,
cocrystal salt, or cocrystal salt solvate according to Table 1.
Out of the 759 627 CSD entries, 227 230 organic entries
with 3D coordinates, no errors, and no disorder were studied
Table 1. Number of Each Residue Type for the Main Classes
and for the Subclasses Proposed Herea
aA single-component crystal is listed for completeness.
Figure 4. Visualization of the new classiﬁcation scheme, inspired by
the proposal of Aitipamula et al. Corresponding to Table 1, we see
three main classes (represented by three colored circles) that create
seven subclasses, which are visible as diﬀerent colors.
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here. The refcodes of the multicomponent CSD entries in this
data set and the classes assigned can be found in the Supporting
Information.
Postprocessing. Sometimes, 3D data of a solvent (i.e.,
coordinates and connectivity) are missing in a CSD entry, even
when the presence of its structure is conﬁrmed in 2D. In this
case, ncof cannot be correctly determined using eq 1. This
inconsistency is especially common for water molecules, for
which coordinates are often not determined. Because of the
frequency of this problem for water and the simplicity of its
molecular structure, we have checked and corrected for this
problem in the case of water molecules.
Disorder and errors in the 3D data can cause erroneous
classiﬁcation, which is why we use ConQuest to include only
crystals labeled as no disorder and no errors. Some entries in
the CSD, however, do show disordered atoms or errors but are
not labeled as such by ConQuest. Our data set will therefore
contain some disorder and error entries. Disorder, partial
absence of 3D data, and delocalized charges sometimes cause
an erroneous classiﬁcation by our software. We performed a
targeted search on such entries and found that 339 entries were
misclassiﬁed due to these data inconsistencies. We further
ignored the rare and exotic cases of solvent solvates, that is,
crystal structures composed of merely solvent residues.
A total of 146 ZR = 1 crystals in true salts and true cocrystals
were reassigned to the single-component class, 112 ZR = 2
crystals in salt solvates and cocrystal solvates were reassigned to
true solvates, 14 ZR = 2 cocrystal salts were reassigned to true
salt, and 67 ZR = 3 cocrystal salt solvates were reassigned to the
salt solvate class.
■ RESULTS AND DISCUSSION
The data set contains 54 505 organic multicomponent CSD
entries (24.0% of all organic entries in the set), which were
classiﬁed into seven subclasses, using our proposed scheme.
Table 2 shows the distribution of crystals over the subclasses
for diﬀerent ZR and for all multicomponent crystals. For each
subclass, we will present one example from the CSD, all of
which contain an INA residue. INA is a popular coformer14−16
often used in cocrystallization screens. Its single-component
crystal structure is shown in Figure 5a. All examples, except for
the cocrystal salt solvate, are from the organic subset.
Crystals with ZR = 2. Binary crystals (ZR = 2) represent the
majority of multicomponent crystals in the data set, with a total
number of 42 299 (77.6%). These can only be true solvates,
true salts, or true cocrystals, and the distribution along these is
plotted in the histogram in Figure 7 (upper panel). The
majority of binary crystals are a solvate (43.0%) or salt (43.6%);
cocrystals represent one-eighth (13.4%) of binary crystals in the
CSD. Figure 5b−d show binary INA crystals each of a diﬀerent
subclass. The solvate crystal (b) involves an OH···N interaction
between acetic acid and the pyridine in INA (both residues are
neutral).17 The salt (d) is that of protonated INA and 3,5-
dinitrosalicylate. The cocrystal of INA carbamazepine (c) has
two known polymorphs;18 shown here is the stable variant of
the two.
Crystals with ZR = 3. The 10 914 ternary crystals (ZR = 3)
represent 20.0% of multicomponent entries. These crystals can
be one of six classes: in addition to the three ZR = 2 classes,
there are salt solvates, cocrystal solvates, and cocrystal salts. The
histogram in Figure 7 (middle panel) shows the distribution of
ternary crystals along these six subclasses. The vast majority are
salt solvates (65.6%), like the one shown in Figure 6a: an INA−
pyromellitic acid ion pair with water. Figure 6b shows an INA−
4,5-dichloro-phthalate ion pair with coformer 4,5-dichloro
methyl phthalate, which is one of the 1114 cocrystal salts
(10.2%) in the ternary subset. The fourth largest ternary class is
the cocrystal solvate (8.5%), an example of which is shown in
Figure 6c. This is an INA norﬂoxacin cocrystal pair with a
chloroform solvent residue. Norﬂoxacin is a zwitterion, but it
has no net charge and is therefore considered a coformer rather
than an ion.
Crystals with ZR ≥ 4. Crystals with four or more residues
(ZR ≥ 4) are more rare, making up less than 3% of the
multicomponent crystal population. In addition to the six ZR =
3 classes, these crystals can also be cocrystal salt solvates, which
gives a total of seven possible subclasses for quaternary and
higher order crystals. A cocrystal salt solvate contains all three
residue types. The occurrence of each subclass for quaternary
crystals is plotted in the histogram in Figure 7 (lower panel).
The asymmetric unit of a cocrystal salt solvate is shown in
Figure 6d, where INA is the coformer, the ion pair is formed by
a positively charged zinc complex cation with a 1,5-naphtalene-
Table 2. Classiﬁcation of Multicomponent Crystals in the CSD
true solvate true salt true cocrystal salt solvate
cocrystal
solvate cocrystal salt cocrystal salt solvate total
ZR = 2 18 192 (33.4%) 18 422 (33.8%) 5685 (10.4%) 42 299 (77.6%)
ZR = 3 937 (1.7%) 678 (1.2%) 88 (0.2%) 7164 (13.1%) 933 (1.7%) 1.114 (2.0%) 10 914 (20.0%)
ZR > 3 32 (0.1%) 17 (0.0%) 1 (0.0%) 508 (0.9%) 104 (0.2%) 47 (0.1%) 583 (1.1%) 1292 (2.4%)
total 19 161 (35.2%) 19 117 (35.1%) 5774 (10.6%) 7.672 (14.1%) 1.037 (1.9%) 1.161 (2.1%) 583 (1.1%) 54 505 (100.0%)
Figure 5. Single-component and three binary isonicotinamide (INA)
crystals in the CSD. (a) Single-component crystal, EHOWIH05.15 (b)
True solvate: INA with acetic acid, JAWWAG.17 (c) True cocrystal:
INA with carbamazepine, LOFKIB.18 (d) True salt: INA ion with 3,5-
dinitrosalicylate, UQACIZ.19
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disulfonate anion (DNS), and the water molecules act as
solvent. This is a metalorganic crystal, which is not part of the
organic subset of the CSD, and is used for illustration purposes
only. In the ZR ≥ 4 subset, most crystals are cocrystal salt
solvates (45.1%). Salt solvates are also abundant, 508 (39.3%),
and cocrystal solvates, cocrystals salts, and true solvates occur
frequently (104, 47, and 32 CSD entries, respectively), but true
salts and cocrystals are rare, with only 17 and 1 quaternary
crystals classiﬁed as such (both <2%).
Classiﬁcation of All Multicomponent Crystals. The
residue types (solvent, ion, coformer) in a multicomponent
crystal determine its subclass according to Table 1. A clear
distinction between solvents and coformers was applied on the
basis of a list of 80 solvents that can be expanded. The
distinction between ions and neutral residues is less
straightforward, but it is overcome here by adopting the atomic
charges provided by the CCDC. The ability to label residues
uniquely allows us to unambiguously classify multicomponent
crystals. In a recent paper,24 Kelley et al. argue that a restrictive
classiﬁcation “will lead to misassumptions about physicochem-
ical properties”, especially in the case of crystals that contain
both ionic and neutral residues or that show partial charge
transfer. Our classiﬁcation system deals with this issue by
having subclasses speciﬁcally for these crystals of ionic and
neutral residues: the cocrystal salt, salt solvate, and cocrystal salt
solvate classes. The issue with partial charge transfer, however,
is avoided rather than resolved.
With this classiﬁcation system, we have successfully classiﬁed
all multicomponent organic crystals in the CSD into seven
subclasses that are mutually exclusive. All subclasses are
relevant in terms of frequency of occurrence. We have found
as many as 12 206 ternary and higher order crystals (ZR ≥ 3),
very few of which are true solvates, salts, or cocrystals (1753).
Classiﬁcation attempts thus far have mainly dealt with binary
crystals and thus only with true solvates, salts, and cocrystals.
The high number of crystals with ZR ≥ 3 shows that
multicomponent classiﬁcation has to go beyond these tradi-
tional classes.
So far, most multicomponent API crystals are true solvates,
true salts, or salt solvates. The number of acceptable
counterions is in the range of 70 residues (excluding polymers),
whereas the potential number of acceptable coformers is much
higher: there are 304 substances on the GRAS lists and over
3000 substances on the EAFUS list. Therefore, the number of
possible acceptable crystals (in terms of safety) for APIs
increases considerably when coformers are considered for
multicomponent crystallization. Table 2 shows that cocrystal-
lization is already a commonly observed phenomenon: 5774
true cocrystals were found in the CSD (10.6%), indicating that
a wide range of new possibilities exists for the pharmaceutical
industry. Furthermore, cocrystal solvates, cocrystal salts, and
cocrystal salt solvates become available by not limiting the
amount of components in drug design to two salt solvates,
totalling 19.2% of the data set studied here. In other words, the
size of the subclasses at the intersection of the true classes (see
Figure 1a) is signiﬁcant, and combinations of ion pairs,
solvents, and coformers are therefore viable options and can be
considered for API crystallization.
The notion that cocrystals and salts are in some cases very
similar to each other led Aitipamula et al.8 to conclude that one
regulatory class for cocrystals and salts should suﬃce. We agree
that it is often diﬃcult to make an unambiguous classiﬁcation
for a compound close to a border between two (sub)classes.
However, while some cocrystals and salts are very similar,
others are very dissimilar because the nature of interactions in
cocrystals can diﬀer greatly from the ionic interaction of salts.
This is the main reason to choose two separate regulatory
Figure 6. Four multicomponent isonicotinamide (INA) crystals in the
CSD. (a) Salt solvate: INA+, a pyromellitic acid counterion, water,
HEVPUU.20 (b) Cocrystal salt: INA+, a phthalate counterion, a
monomethyl-phthalic acid coformer, LORWOF.21 (c) Cocrystal
solvate: INA, norﬂoxacin, chloroform, VETVUM.22 (d) Cocrystal
salt solvate: a zinc complex, a 1,5-naphthalenedisulfonate counterion,
an INA coformer, water, FUZGOX.23
Figure 7. ZR = 2, ZR = 3, and ZR > 3 distributions over the possible
classes.
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classes, like the FDA did. Moreover, we see from Table 2 that
one cocrystal exists for every three salts.
The results in this article were obtained using a biased
collection of data, the CSD. The CSD does not represent a
random subset of all possible crystals but, rather, a biased
subset where researchers chose (combinations of) residues to
study and publish. As a result, the collection of crystals in the
CSD is aﬀected not only by the limitations of crystallization but
also by current scientiﬁc and commercial interests. Also, we
note again the additional but limited bias in the cocrystal class,
which will contain some false positives that are actually solvates,
when a solvent is not on the used list of known solvents.
■ CONCLUSIONS
We have deﬁned rules to come to a feasible classiﬁcation
system for multicomponent crystals, inspired by the earlier
work of Aitipamula et al.8 The present classiﬁcation entails
seven mutually exclusive subclasses and associated rules, based
on the residue types in the crystal, thereby resolving the
problem of overlapping classes present in the classiﬁcation of
Aitipamula et al. Testing the proposed classiﬁcation on 54 505
multicomponent entries from the CSD showed a world of
opportunities for multicomponent API crystallization: 5774
cocrystals were identiﬁed, as were 2781 cocrystal salts, cocrystal
solvates, and cocrystal salt solvates. The number of acceptable
counterions in pharmaceuticals is very limited, whereas the
potential number of acceptable coformers is much higher (e.g.,
from the GRAS and EAFUS lists). Therefore, by including
coformers and including more than two residues, the number of
possible acceptable crystals (in terms of safety) increases
considerably.
The signiﬁcant number of entries found in the CSD for each
subclass, without any overlap, shows that we have deﬁned
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Uhaŕriz, M. C. Drug Dev. Ind. Pharm. 1997, 23, 1095−1098.
(2) Fini, A.; Fazio, G.; Feroci, G. Int. J. Pharm. (Amsterdam, Neth.)
1995, 126, 95−102.
(3) Steed, J. W. Trends Pharmacol. Sci. 2013, 34, 185−193.
(4) Wood, P. A.; Feeder, N.; Furlow, M.; Galek, P. T. A.; Groom, C.
R.; Pidcock, E. CrystEngComm 2014, 16, 5839−5848.
(5) Generally Recognized as Safe (GRAS); U.S. FDA: College Park,
MD, 2011. http://www.fda.gov/Food/IngredientsPackagingLabeling/
GRAS/default.htm (accessed April 4, 2016).
(6) Everything Added to Food in the United States (EAFUS); U.S. FDA,
2011. http://www.fda.gov/food/ingredientspackaginglabeling/
foodadditivesingredients/ucm115326.htm (accessed April 4, 2016).
(7) Guidance for Industry: Regulatory Classiﬁcation of Pharmaceutical
Co-crystals; U.S. FDA: Silver Spring, MD, 2011.
(8) Aitipamula, S.; et al. Cryst. Growth Des. 2012, 12, 2147−2152.
(9) Guidance for Industry: Regulatory Classiﬁcation of Pharmaceutical
Co-crystals; U.S. FDA: Silver Spring, MD, 2013. http://www.fda.gov/
downloads/drugs/guidancecomplianceregulatoryinformation/
guidances/ucm281764.pdf.
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